ASCO 2021 - Physician's Weekly


Advertisement

ASCO 2021

Long-term results from ground-breaking melanoma trials

After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma. In the phase 3 CheckMate 067...

Post-nephrectomy pembrolizumab improves disease-free survival

First results of the phase 3 KEYNOTE 564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC). Nephrectomy...

Loading

Advertisement

For latest news and updates
Email-id is invalid